Clinuvel Pharmaceuticals Ltd ADR
CUVLHealthcare·Biotechnology·Australia·Micro·NASD·Nov 10 • 3:59 PM ET
5.190.00 (0.00%)
2026-11-11 14:23 CET
Market cap
262.03 USD m
Revenue, TTM
64.31 USD m
Net income, TTM
23.33 USD m
Free cash flow, TTM
24.81 USD m
EPS diluted, TTM
0.46
P/E
11.29
Price
CUVL against its 20, 50 and 200-day averages2050200miss
41.8% under 8.92 on 29 Dec 2025. Last 15 sessions, 27.0% high to low
Profile
CUVL52-week range, 9% of the way up
4.818.92
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
| IPO | Jul 02, 2004 |
|---|---|
| Beta | 0.88 |
| ATR, 14d | 0.26 |
| Rel volume | 0.00 |
| Short float | 0.01% |
| Inst own | 0.04% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | 262.04M |
| Enterprise Value | 88.76M |
| Income | 23.33M |
| Sales | 64.31M |
| Book/sh | 3.75 |
| Cash/sh | 3.46 |
| Dividend Est. | 0.04 (0.74%) |
| Dividend TTM | 0.04 (0.69%) |
| Dividend Ex-Date | Sep 08, 2026 |
| Dividend Gr. 3/5Y | 0.00% 24.57% |
| Payout | 6.19% |
| Employees | - |
| IPO | Jul 02, 2004 |
Ratios
| P/E | 11.29 |
|---|---|
| Forward P/E | 10.55 |
| PEG | 0.93 |
| P/S | 4.07 |
| P/B | 1.38 |
| P/C | 1.50 |
| P/FCF | 10.56 |
| EV/EBITDA | 3.10 |
| EV/Sales | 1.38 |
| Quick Ratio | 14.45 |
| Current Ratio | 14.81 |
| Debt/Eq | 0.01 |
| LT Debt/Eq | 0.01 |
| Option/Short | No / Yes |
Earnings
| EPS (ttm) | 0.46 |
|---|---|
| EPS next Y | 0.49 |
| EPS next Q | 0.18 |
| EPS this Y | -0.97% |
| EPS next Y | 3.44% |
| EPS next 5Y | 11.32% |
| EPS past 3/5Y | 3.32% 4.25% |
| Sales past 3/5Y | 6.54% 12.24% |
| EPS Y/Y TTM | -0.47% |
| Sales Y/Y TTM | 5.04% |
| EPS Q/Q | 16.80% |
| Sales Q/Q | 6.50% |
| Earnings | Aug 26 AMC |
| EPS/Sales Surpr. | 0.91% -1.62% |
Ownership
| Insider Own | - |
|---|---|
| Insider Trans | - |
| Inst Own | 0.04% |
| Inst Trans | -8.30% |
| ROA | 12.16% |
| ROE | 13.45% |
| ROIC | 12.27% |
| Gross Margin | 82.84% |
| Oper. Margin | 43.47% |
| Profit Margin | 36.28% |
| SMA20 | 2.00% |
| SMA50 | -6.55% |
| SMA200 | -24.04% |
| Trades | - |
Technical
| Shs Outstand | 50.43M |
|---|---|
| Shs Float | 37.77M |
| Short Float | 0.01% |
| Short Ratio | 0.15 |
| Short Interest | 0.00M |
| 52W High | 8.92 -41.82% |
| 52W Low | 4.81 7.90% |
| Volatility | 3.80% 4.59% |
| ATR (14) | 0.26 |
| RSI (14) | 47.32 |
| Beta | 0.88 |
| Rel Volume | 0.00 |
| Avg Volume | 13.09K |
| Volume | 0 |
Performance
| Perf Week | 2.27% |
|---|---|
| Perf Month | -7.06% |
| Perf Quarter | -22.31% |
| Perf Half Y | -22.31% |
| Perf YTD | -38.80% |
| Perf Year | -26.85% |
| Perf 3Y | -49.32% |
| Perf 5Y | -78.25% |
| Perf 10Y | -13.70% |
| Recom | 2.14 |
| Target Price | 11.80 |
| Prev Close | 5.19 |
| Price | 5.19 |
| Change % | 0.00% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| IRON | Disc Medicine Inc | 3.85B |
| PTN | Palatin Technologies Inc | 12.23M |
| RYTM | Rhythm Pharmaceuticals Inc | 7.90B |
| ABEO | Abeona Therapeutics Inc | 140.01M |
| FENC | Fennec Pharmaceuticals Inc | 371.01M |
| KRYS | Krystal Biotech Inc | 9.07B |
| INCY | Incyte Corp | 23.64B |
| ARQT | Arcutis Biotherapeutics Inc | 3.48B |
| SNGX | Soligenix Inc | 7.59M |
| VRCA | Verrica Pharmaceuticals Inc | 60.47M |
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2026S2 | 2026-08-26 | 0.353 | 0.350 | 0.335 | 41.54 | 42.23 | 3 |
| 2026S1 | 2026-02-25 | 0.147 | 0.198 | 0.135 | 26.22 | 25.66 | 2 |
| 2027S1 | - | - | 0.180 | - | - | 26.01 | 3 |
| 2027S2 | - | - | 0.320 | - | - | 41.78 | 3 |
| 2028S1 | - | - | 0.180 | - | - | 29.66 | 3 |
| 2028S2 | - | - | 0.349 | - | - | 49.34 | 3 |
| 2029S1 | - | - | 0.580 | - | - | 97.24 | 2 |
| 2029S2 | - | - | 0.598 | - | - | 129.3 | 2 |
| 2030S1 | - | - | 0.215 | - | - | - | 1 |
| 2030S2 | - | - | 2.620 | - | - | - | 1 |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2025FY | 0.469 | 0.510 | 0.465 | 62.00 | 64.31 |
| 2026FY | 0.480 | 0.495 | 0.483 | 67.62 | 68.66 |
| 2027FY | - | 0.476 | - | - | 66.40 |
| 2028FY | - | 0.492 | - | - | 70.27 |
| 2029FY | - | 0.663 | - | - | 92.69 |
| 2030FY | - | 2.835 | - | - | 270.96 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2027S1 | S | 2026-11-10 | 3 | 0 | 0 | 26.01 | 25.53 | 26.54 |
| 2027S1 | S | 2026-09-18 | 3 | 1 | 0 | 26.01 | 25.53 | 26.54 |
| 2027S1 | S | 2026-09-01 | 3 | 1 | 1 | 26.01 | 25.53 | 26.54 |
| 2027S1 | S | 2026-08-27 | 3 | 1 | 1 | 26.07 | 25.53 | 26.54 |
| 2027S1 | S | 2026-07-21 | 1 | 0 | 1 | 25.50 | 25.50 | 25.50 |
| 2027S1 | S | 2026-06-06 | 1 | 0 | 0 | 27.15 | 27.15 | 27.15 |
| 2027S1 | S | 2026-05-12 | 2 | 0 | 0 | 27.24 | 27.15 | 27.33 |
| 2027S1 | S | 2026-04-23 | 2 | 0 | 1 | 27.24 | 27.15 | 27.33 |
| 2027S1 | S | 2026-02-27 | 2 | 0 | 1 | 27.17 | 27.01 | 27.33 |
| 2027S1 | S | 2026-02-26 | 2 | 0 | 1 | 27.12 | 26.91 | 27.33 |
| 2027S1 | S | 2026-01-20 | 1 | 1 | 0 | 27.87 | 27.87 | 27.87 |
| 2027S1 | S | 2026-01-19 | 1 | 1 | 0 | 27.74 | 27.74 | 27.74 |
| 2027S1 | S | 2025-12-03 | 1 | 0 | 0 | 27.26 | 27.26 | 27.26 |
| 2027S1 | S | 2025-12-02 | 1 | 0 | 0 | 27.14 | 27.14 | 27.14 |
Estimate history
| EPS, annual | 0.207 | 0.262 | 0.2 | 0.361 | 0.293 | 0.397 | 0.458 | 0.465 | 0.453 |
|---|---|---|---|---|---|---|---|---|---|
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| EPS, quarterly | |||||||||
| Period | |||||||||
| Sales, annual | 19.746 | 22.209 | 21.831 | 35.776 | 47.667 | 52.687 | 57.79 | 61.536 | 63.713 |
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Sales, quarterly | |||||||||
| Period | |||||||||
| Shares, annual | 47.824 | 48.961 | 49.41 | 49.41 | 49.41 | 49.41 | 50.078 | 50.124 | 50.428 |
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Shares, quarterly | |||||||||
| Period |
Income statement, annual
| Metric | TTM | 2026FY | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 64.31 | 63.71 | 61.54 | 57.79 | 52.69 | 47.67 | 35.78 | 21.83 | 22.21 |
| Cost of Goods Sold Incl. D&A | 11.04 | 10.72 | 21.06 | 19.83 | 18.66 | 13.86 | 9.52 | 9.48 | - |
| Gross Profit | 53.27 | 53.00 | 40.48 | 37.96 | 34.03 | 33.81 | 26.25 | 12.36 | - |
| Selling, General and Administrative Excl. Other | 25.32 | 25.48 | 13.73 | 9.39 | 6.51 | 9.82 | 6.35 | 5.52 | 10.12 |
| Research and Development | 12.55 | 12.26 | 4.79 | 1.54 | 0.85 | 0.89 | 0.41 | 0.23 | 4.92 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | 27.96 | 27.52 | 26.75 | 28.57 | 27.52 | 23.99 | 19.91 | 6.84 | 11.94 |
| Interest Expense | - | 0.06 | 0.03 | 0.03 | - | - | - | 0.02 | 0.02 |
| Unusual Expense | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.16 | -0.10 | -0.08 | - |
| Net Income Before Taxes | 32.79 | 32.30 | 33.39 | 33.21 | 30.66 | 24.89 | 19.17 | 7.74 | 12.96 |
| Income Taxes | 9.46 | 9.31 | 9.96 | 9.86 | 10.07 | 9.75 | 0.73 | -2.35 | -0.01 |
| Consolidated Net Income | 23.33 | 22.98 | 23.43 | 23.36 | 20.59 | 15.14 | 18.44 | 10.09 | 12.97 |
| Net Income From Continuing Operations | 23.33 | 22.98 | 23.43 | 23.36 | 20.59 | 15.14 | 18.44 | 10.09 | 12.97 |
| Net Income | 23.33 | 22.98 | 23.43 | 23.36 | 20.59 | 15.14 | 18.44 | 10.09 | 12.97 |
| EPS (Recurring) | 0.46 | 0.45 | 0.46 | 0.46 | 0.40 | 0.29 | 0.36 | 0.20 | 0.26 |
| EPS (Basic, Before Extraordinaries) | 0.46 | 0.46 | 0.47 | 0.47 | 0.42 | 0.31 | 0.37 | 0.20 | 0.27 |
| EPS (Diluted) | 0.46 | 0.45 | 0.47 | 0.46 | 0.40 | 0.29 | 0.36 | 0.20 | 0.26 |
| EBITDA | 28.63 | 28.19 | 27.52 | 29.32 | 28.05 | 24.54 | 20.55 | 7.13 | 12.09 |
| Non-Operating Income (Expense) | 4.83 | 4.83 | 6.66 | 4.67 | 3.14 | 0.74 | -0.83 | 0.82 | 1.03 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 1.12 | 1.11 | 0.91 | 2.80 | 4.23 | 3.11 | 1.36 | 0.78 | 0.07 |
| Price To Earnings Ratio | 11.20 | 11.20 | 13.32 | 24.19 | 32.13 | 27.63 | 75.29 | 79.59 | 94.95 |
| Price To Sales Ratio | 5.63 | 5.67 | 5.57 | 9.06 | 11.71 | 11.09 | 32.94 | 40.82 | 52.79 |
| Gross Margin | 82.84 | 83.18 | 65.78 | 65.68 | 64.59 | 70.93 | 73.38 | 56.60 | - |
| Operating Margin | 43.47 | 43.19 | 43.48 | 49.44 | 52.23 | 50.34 | 55.65 | 31.31 | 53.76 |
| Net Margin | 36.28 | 36.07 | 38.07 | 40.41 | 39.08 | 31.77 | 51.54 | 46.22 | 58.41 |
| Shares Outstanding | 50.43 | 50.43 | 50.12 | 50.08 | 49.41 | 49.41 | 49.41 | 49.41 | 48.96 |
| Market Capitalization | 262.03 | 262.03 | 340.84 | 491.02 | 591.69 | 507.44 | 1,129.03 | 867.15 | 1,169.67 |
Income statement, quarterly
| Metric | 2026S2 | 2026S1 | 2025S2 | 2025S1 | 2024S2 | 2024S1 | 2023S2 | 2023S1 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 40.11 | 24.20 | 37.66 | 23.56 | 36.80 | 21.05 | 33.08 | 19.67 |
| Cost of Goods Sold Incl. D&A | 0.44 | 10.60 | 11.91 | 9.09 | 9.82 | 10.01 | 10.45 | 5.65 |
| Gross Profit | 39.67 | 13.60 | 25.76 | 14.48 | 26.98 | 11.04 | 22.63 | 14.02 |
| Selling, General and Administrative Excl. Other | 18.90 | 6.42 | 8.64 | 5.03 | 5.78 | 3.65 | 3.76 | 5.32 |
| Research and Development | 10.33 | 2.22 | 2.90 | 1.88 | 1.05 | 0.49 | 0.46 | 0.40 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | 20.78 | 7.18 | 17.11 | 9.45 | 21.20 | 7.40 | 18.87 | 8.70 |
| Unusual Expense | 0.00 | -0.00 | 0.00 | -0.00 | 0.00 | -0.36 | 0.00 | -0.01 |
| Net Income Before Taxes | 23.24 | 9.55 | 18.79 | 14.50 | 23.61 | 9.66 | 20.93 | 9.78 |
| Income Taxes | 6.75 | 2.71 | 4.77 | 5.19 | 7.35 | 2.53 | 7.95 | 2.15 |
| Consolidated Net Income | 16.49 | 6.84 | 14.02 | 9.30 | 16.26 | 7.14 | 12.98 | 7.63 |
| Net Income From Continuing Operations | 16.49 | 6.84 | 14.02 | 9.30 | 16.26 | 7.14 | 12.98 | 7.63 |
| Net Income | 16.49 | 6.84 | 14.02 | 9.30 | 16.26 | 7.14 | 12.98 | 7.63 |
| EPS (Recurring) | 0.32 | 0.14 | 0.28 | 0.19 | 0.32 | 0.13 | 0.25 | 0.15 |
| EPS (Basic, Before Extraordinaries) | 0.33 | 0.14 | 0.28 | 0.19 | 0.32 | 0.14 | 0.26 | 0.15 |
| EPS (Diluted) | 0.32 | 0.14 | 0.28 | 0.19 | 0.32 | 0.14 | 0.25 | 0.15 |
| EBITDA | 21.12 | 7.51 | 17.48 | 9.85 | 21.58 | 7.77 | 19.15 | 8.95 |
| Non-Operating Income (Expense) | 2.46 | 2.37 | 1.68 | 5.05 | 2.41 | 1.91 | 2.06 | 1.08 |
| Stock Option Compensation Expense | 0.64 | 0.48 | 0.44 | 0.47 | 0.21 | 2.58 | 2.44 | 1.79 |
| Price To Earnings Ratio | 11.20 | 18.21 | 13.32 | 16.49 | 24.19 | 26.50 | 32.13 | 48.28 |
| Price To Sales Ratio | 5.63 | 6.80 | 5.61 | 6.22 | 9.01 | 10.40 | 11.70 | 15.46 |
| Gross Margin | 98.91 | 56.19 | 68.39 | 61.43 | 73.31 | 52.46 | 68.40 | 71.28 |
| Operating Margin | 51.80 | 29.67 | 45.44 | 40.10 | 57.61 | 35.13 | 57.04 | 44.21 |
| Net Margin | 41.11 | 28.28 | 37.22 | 39.49 | 44.17 | 33.90 | 39.25 | 38.79 |
| Shares Outstanding | 50.43 | 50.18 | 50.12 | 50.06 | 50.08 | 50.13 | 49.41 | 49.41 |
| Market Capitalization | 262.03 | 425.56 | 340.84 | 385.47 | 491.02 | 554.16 | 591.69 | 728.06 |
Balance sheet, annual
| Metric | 2026FY | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 174.62 | 146.87 | 122.80 | 104.38 | 83.56 | 62.08 | 45.95 | 38.08 | 26.75 |
| Short Term Receivables | 16.25 | 18.00 | 17.52 | 14.79 | 11.14 | 12.08 | 4.55 | 2.92 | 3.76 |
| Inventories | 4.77 | 5.78 | 7.10 | 6.34 | 1.26 | 2.39 | 0.89 | 1.50 | 0.47 |
| Other Current Assets | 1.55 | 1.69 | 0.89 | 0.71 | 0.71 | 0.66 | 0.35 | 0.42 | 0.25 |
| Total Current Assets | 197.19 | 172.34 | 148.31 | 126.22 | 96.67 | 77.21 | 51.74 | 42.91 | 31.23 |
| Net Property, Plant & Equipment | 6.41 | 4.67 | 5.16 | 1.90 | 1.86 | 1.95 | 1.65 | 0.50 | 0.12 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.13 | 0.12 | 0.12 | 0.12 | 0.13 | 0.14 | 0.13 | 0.13 | 0.14 |
| Deferred Tax Assets | 1.30 | 1.38 | 1.32 | 1.25 | 0.93 | 2.20 | 2.62 | 0.21 | 0.21 |
| Other Assets | 0.15 | 0.14 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 205.17 | 178.65 | 155.00 | 129.49 | 99.58 | 81.51 | 56.14 | 43.75 | 31.70 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.27 | 0.28 | 0.25 | 0.20 | 0.22 | 0.19 | 0.15 | 0.18 | 0.00 |
| Accounts Payable | 0.89 | 1.67 | 1.57 | 1.86 | 0.18 | 1.74 | 0.98 | 1.05 | 0.32 |
| Income Tax Payable | 4.65 | 9.53 | 10.59 | 10.71 | 5.01 | - | - | - | - |
| Other Current Liabilities | 7.51 | 6.35 | 4.44 | 4.20 | 4.04 | 4.60 | 4.56 | 2.24 | 2.25 |
| Total Current Liabilities | 13.31 | 17.83 | 16.84 | 16.97 | 9.44 | 6.54 | 5.69 | 3.48 | 2.56 |
| Long Term Debt | 1.07 | 0.06 | 0.34 | 0.47 | 0.65 | 0.78 | 0.76 | 0.12 | 0.00 |
| Provision for Risks Charges | 0.18 | 0.06 | 0.11 | 0.09 | 0.07 | 0.06 | 0.07 | 0.02 | 0.01 |
| Deferred Tax Liabilities | 1.56 | 2.80 | 2.13 | 2.38 | 3.08 | - | - | - | - |
| Other Liabilities | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 16.12 | 20.84 | 19.42 | 19.90 | 13.24 | 7.38 | 6.52 | 3.62 | 2.58 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 189.05 | 157.81 | 135.58 | 109.59 | 86.34 | 74.13 | 49.62 | 40.13 | 29.12 |
| Total Shareholders Equity | 189.05 | 157.81 | 135.58 | 109.59 | 86.34 | 74.13 | 49.62 | 40.13 | 29.12 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 189.05 | 157.81 | 135.58 | 109.59 | 86.34 | 74.13 | 49.62 | 40.13 | 29.12 |
| Total Liabilities & Stockholders Equity | 205.17 | 178.65 | 155.00 | 129.49 | 99.58 | 81.51 | 56.14 | 43.75 | 31.70 |
| Book Value Per Share | 3.75 | 3.15 | 2.71 | 2.22 | 1.75 | 1.50 | 1.00 | 0.82 | 0.61 |
| Tangible Book Value Per Share | 3.75 | 3.15 | 2.70 | 2.22 | 1.74 | 1.50 | 1.00 | 0.82 | 0.61 |
| Price to Book Ratio | 1.38 | 2.53 | 4.03 | 6.27 | 6.51 | 18.74 | 21.26 | 37.66 | 18.23 |
| Return on Assets | 11.98 | 14.04 | 16.42 | 17.98 | 16.72 | 26.79 | 20.20 | 34.38 | 38.20 |
| Return on Equity | 13.25 | 15.97 | 19.05 | 21.02 | 18.87 | 29.54 | 22.49 | 37.46 | 42.17 |
| Return on Invested Capital | 12.09 | 14.84 | 17.18 | 18.71 | 17.41 | 24.62 | 20.03 | 32.23 | 35.18 |
| Quick Ratio | 14.45 | 9.34 | 8.39 | 7.06 | 10.10 | 11.45 | 8.94 | 11.90 | 11.99 |
| Current Ratio | 14.81 | 9.66 | 8.81 | 7.44 | 10.24 | 11.81 | 9.10 | 12.33 | 12.18 |
Cash flow, annual
| Metric | TTM | 2026FY | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | - | 22.98 | 23.43 | 23.36 | 20.59 | 15.14 | 18.44 | 10.09 | 12.97 |
| Depreciation | - | 0.67 | 0.74 | 0.71 | 0.50 | 0.52 | 0.61 | 0.29 | 0.15 |
| Other Funds (Non Cash) | - | 3.57 | 1.02 | 4.44 | 5.91 | 4.58 | 3.17 | 0.27 | -0.49 |
| Funds from Operations | 28.22 | 27.22 | 25.19 | 28.51 | 27.00 | 24.65 | 22.88 | 8.29 | 12.62 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | - | -2.21 | 1.42 | -4.22 | -2.16 | 4.27 | -8.51 | 1.22 | 0.58 |
| Income Taxes Payable | - | -6.82 | -0.07 | -0.51 | 5.35 | 5.21 | - | - | - |
| Cash from Operating Activities | 25.93 | 25.01 | 26.61 | 24.28 | 24.83 | 28.92 | 14.36 | 9.51 | 13.20 |
| Capital Expenditures | -1.13 | -1.09 | -0.19 | -3.65 | -0.69 | -0.32 | -0.64 | -0.60 | -0.18 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Purchase or Sale of Investments | -26.36 | -25.42 | -30.71 | -15.37 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | -26.36 | -25.42 | -30.71 | -15.37 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -27.48 | -26.51 | -30.90 | -19.03 | -0.69 | -0.32 | -0.64 | -0.60 | -0.18 |
| Cash Dividends Paid | -1.76 | -1.70 | -1.62 | -1.62 | -1.33 | -0.90 | -0.92 | -0.82 | -0.68 |
| Change in Capital Stock | -0.01 | -0.01 | -0.16 | -0.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Common Pref Stock | -0.40 | -0.38 | -0.29 | -3.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.39 | 0.38 | 0.12 | 2.72 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Proceedsfrom Stock Options | 0.39 | 0.38 | 0.12 | 2.72 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -1.94 | -1.87 | -1.90 | -2.34 | -1.51 | -1.09 | -1.10 | -1.00 | -0.74 |
| Exchange Rate Effect | -1.17 | -1.13 | 1.54 | -0.75 | 1.12 | 0.64 | -0.73 | 0.45 | 0.65 |
| Net Change in Cash | -4.66 | -4.49 | -4.65 | 2.17 | 23.75 | 28.15 | 11.89 | 8.36 | 12.93 |
| Free Cash Flow | 24.81 | 23.93 | 26.42 | 20.63 | 24.14 | 28.60 | 13.73 | 8.92 | 13.02 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price to Free Cash Flow | 15.70 | 16.26 | 13.82 | 27.55 | 27.04 | 19.08 | 92.03 | 110.08 | 95.06 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 4.40 | 0.66 | -2.35 | -0.01 |
Balance sheet, quarterly
| Metric | 2026S2 | 2026S1 | 2025S2 | 2025S1 | 2024S2 | 2024S1 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 174.62 | 155.38 | 146.87 | 122.73 | 122.80 | 119.04 |
| Short Term Receivables | 16.25 | 11.06 | 18.00 | 10.08 | 17.52 | 8.92 |
| Inventories | 4.77 | 5.61 | 5.78 | 5.82 | 7.10 | 8.57 |
| Other Current Assets | 1.55 | 2.26 | 1.69 | 2.26 | 0.89 | 0.97 |
| Total Current Assets | 197.19 | 174.30 | 172.34 | 140.90 | 148.31 | 137.49 |
| Net Property, Plant & Equipment | 6.41 | 4.32 | 4.67 | 4.40 | 5.16 | 5.38 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.13 | 0.12 | 0.12 | 0.11 | 0.12 | 0.13 |
| Deferred Tax Assets | 1.30 | 0.95 | 1.38 | 0.75 | 1.32 | 1.35 |
| Other Assets | 0.15 | 0.15 | 0.14 | 0.08 | 0.09 | 0.09 |
| Total Assets | 205.17 | 179.85 | 178.65 | 146.25 | 155.00 | 144.44 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.27 | 0.20 | 0.28 | 0.24 | 0.25 | 0.24 |
| Accounts Payable | 6.41 | 7.12 | 6.52 | 3.50 | 4.75 | 4.42 |
| Income Tax Payable | 4.65 | 2.91 | 9.53 | 3.18 | 10.59 | 14.23 |
| Other Current Liabilities | 1.99 | 1.67 | 1.50 | 1.19 | 1.26 | 1.16 |
| Total Current Liabilities | 13.31 | 11.90 | 17.83 | 8.11 | 16.84 | 20.05 |
| Long Term Debt | 1.07 | 0.01 | 0.06 | 0.20 | 0.34 | 0.49 |
| Deferred Tax Liabilities | 1.56 | 1.75 | 2.80 | 3.27 | 2.13 | 1.90 |
| Other Liabilities | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 16.12 | 13.79 | 20.84 | 11.70 | 19.42 | 22.54 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 189.05 | 166.06 | 157.81 | 134.54 | 135.58 | 121.90 |
| Total Shareholders Equity | 189.05 | 166.06 | 157.81 | 134.54 | 135.58 | 121.90 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 189.05 | 166.06 | 157.81 | 134.54 | 135.58 | 121.90 |
| Total Liabilities & Stockholders Equity | 205.17 | 179.85 | 178.65 | 146.25 | 155.00 | 144.44 |
| Book Value Per Share | 3.75 | 3.31 | 3.15 | 2.69 | 2.71 | 2.43 |
| Tangible Book Value Per Share | 3.75 | 3.31 | 3.15 | 2.69 | 2.70 | 2.43 |
| Price to Book Ratio | 1.38 | 2.69 | 2.53 | 2.84 | 4.03 | 4.98 |
| Return on Assets | 12.16 | 12.79 | 13.98 | 17.59 | 16.45 | 15.90 |
| Return on Equity | 13.45 | 13.88 | 15.90 | 19.93 | 19.08 | 18.60 |
| Return on Invested Capital | 8.67 | 4.12 | 8.88 | 6.90 | 11.96 | 5.83 |
| Quick Ratio | 14.45 | 14.17 | 9.34 | 16.65 | 8.39 | 6.43 |
| Current Ratio | 14.81 | 14.64 | 9.66 | 17.37 | 8.81 | 6.86 |
Cash flow, quarterly
| Metric | 2026S2 | 2026S1 | 2025S2 | 2025S1 | 2024S2 | 2024S1 |
|---|---|---|---|---|---|---|
| Funds from Operations | 20.01 | 8.21 | 15.98 | 8.69 | 11.41 | 17.22 |
| Extraordinary Item | 0.00 | 0.00 | - | - | 0.00 | 0.00 |
| Cash from Operating Activities | 17.72 | 8.21 | 17.38 | 8.69 | 7.17 | 17.22 |
| Capital Expenditures | -1.03 | -0.10 | -0.15 | -0.04 | -0.21 | -3.46 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -25.85 | -0.51 | -10.29 | -19.79 | -8.45 | -6.99 |
| Purchase of Investments | -25.85 | -0.51 | -10.29 | -19.79 | -8.45 | -6.99 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -26.88 | -0.61 | -10.44 | -19.83 | -8.66 | -10.45 |
| Cash Dividends Paid | -0.12 | -1.64 | 0.07 | -1.65 | -0.01 | -1.61 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | -0.01 | 0.00 | 0.01 | -0.17 | -0.50 | 0.00 |
| Repurchase of Common Pref Stock | -0.40 | 0.00 | -0.11 | -0.17 | -3.23 | 0.00 |
| Sale of Common Pref Stock | 0.39 | 0.00 | 0.12 | 0.00 | 2.73 | 0.00 |
| Proceedsfrom Stock Options | 0.39 | 0.00 | 0.12 | 0.00 | 2.73 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -0.16 | -1.78 | 0.08 | -1.94 | -0.63 | -1.72 |
| Exchange Rate Effect | -0.67 | -0.51 | 0.58 | 0.93 | -0.22 | -0.53 |
| Net Change in Cash | -9.98 | 5.32 | 7.59 | -12.15 | -2.34 | 4.52 |
| Free Cash Flow | 16.70 | 8.11 | 17.22 | 8.66 | 6.96 | 13.76 |
| Price to Free Cash Flow | 15.70 | 17.70 | 14.13 | 26.91 | 27.31 | 24.97 |
Revenue breakdown
| Commercial Sales of Goods | 2025: 55.58M 2026: 57.88M |
|---|---|
| Sales Under Special Access Reimbursement Programs | 2025: 5.54M 2026: 6.43M |
| Ireland | 2025: 29.77M 2026: 36.04M |
| Rest of World | 2025: 584.30K 2026: 553.11K |
| United States | 2025: 30.76M 2026: 27.73M |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 0.01% | 0.0M | 37.8M | 12.81K |
| 2026-10-15 | 0.04% | 0.0M | 37.8M | 13.79K |
| 2026-09-30 | 0.03% | 0.0M | 37.8M | 13.25K |
| 2026-09-15 | 0.07% | 0.0M | 37.8M | 12.74K |
| 2026-08-31 | 0.03% | 0.0M | 37.8M | 7.38K |
| 2026-08-14 | 0.00% | 0.0M | 37.8M | 4.10K |
| 2026-07-31 | 0.00% | 0.0M | 37.8M | 4.15K |
Option chain
expiry 2026-11-11| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-10-30 | 20-F | Registration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer. | 2026-06-30 | SEC |
| 2026-10-30 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-30 | SEC |
| 2026-10-15 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-15 | SEC |
| 2026-10-07 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-07 | SEC |
| 2026-10-02 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-02 | SEC |
| 2026-10-01 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-01 | SEC |
| 2026-09-09 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-09-08 | SEC |
| 2026-08-27 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-27 | SEC |
| 2026-08-20 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-20 | SEC |
| 2026-08-12 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-12 | SEC |
| 2026-07-30 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-30 | SEC |
| 2026-07-28 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-28 | SEC |
| 2026-07-27 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-27 | SEC |
| 2026-07-23 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-23 | SEC |
| 2026-07-22 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-21 | SEC |
| 2026-07-22 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-21 | SEC |
| 2026-07-17 | SEC STAFF ACTION | SEC | ||
| 2026-07-17 | CERT | SEC | ||
| 2026-07-17 | 424B3 | SEC | ||
| 2026-07-15 | CORRESP | SEC | ||
| 2026-07-09 | CORRESP | SEC | ||
| 2026-07-06 | CORRESP | SEC | ||
| 2026-06-15 | CORRESP | SEC | ||
| 2026-06-15 | 20FR12B | SEC | ||
| 2026-04-23 | UPLOAD | Upload Submission | SEC | |
| 2026-04-17 | DRSLTR | Correspondence Submission of a DRS filer. Correspondence is not publicly disseminated immediately. The SEC staff may publicly release all or portions of these documents. | SEC | |
| 2026-04-17 | DRS/A | SEC | ||
| 2026-04-07 | UPLOAD | Upload Submission | SEC | |
| 2026-03-30 | DRS/A | SEC | ||
| 2026-03-27 | DRSLTR | Correspondence Submission of a DRS filer. Correspondence is not publicly disseminated immediately. The SEC staff may publicly release all or portions of these documents. | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| UBS Group AG | 0.06% |
| Shade Tree Advisors LLC | 0.04% |
Funds
| Fund | % owned |
|---|---|
| - | |
OakChart. CUVL. Cached 15 minutes.
Some panels did not load: ratings, insider, news.